About Us

Tissue Regeneration Therapeutics (TRT) is a progressive biotechnology company with a focus on the commercial development of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology and its TXP cell therapy products. TRT is the only company in the world to have issued and allowed patents in the USA, Europe, and Australasia, for the extraction of these unique cells from umbilical cord tissue.

TRT has discovered the world's richest source of mesenchymal stromal/stem cells (MSCs) with potent regenerative, angiogenic, anti-inflammatory, and immuno-regulatory properties. Unique advantages of the TRT HUCPVC platform technology are founded on the highly enriched source of these important cells compared to other tissue sources. Specifically, HUCPVCs represent high cell yields at harvest from tissue normally discarded at birth; high frequencies of mesenchymal stromal cells within the harvested population, their increased biological potential compared to cells derived from adult tissues and their inexhaustible supply.

With our partners we create cellular and regenerative strategies that maximize the utility of our platform technology and products - for therapies that address important health care issues of today.

Together, we build very powerful biology.